GMP IPO Watch
HDFC Pharma and Healthcare Fund
Direct Plan · Growth Option · HDFC Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.54% | +3.52% | 161 of 255 |
| 1M | +2.30% | +1.97% | 115 of 255 |
| 3M | +2.51% | -3.45% | 11 of 252 |
| 6M | +17.12% | +2.92% | 6 of 251 |
| YTD | +27.37% | +1.21% | 3 of 255 |
| 1Y | +25.51% | +1.11% | 2 of 232 |
| 2Y | +16.69% | +2.39% | 5 of 187 |
| 3Y | +31.04% | +12.36% | 3 of 142 |
| INCEPTION | +30.18% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +7.26% | +29.66% | -12.76% | 80% | 33% |
| 6M | +13.87% | +38.32% | -8.15% | 87% | 38% |
| 1Y | +24.57% | +67.32% | +1.71% | 100% | 47% |
| 2Y | +22.98% | +34.63% | +12.64% | 100% | 48% |
| 3Y | +29.32% | +31.08% | +27.78% | 100% | 52% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity96.77%
- Debt0.00%
- Cash3.23%
- Other0.00%
Market Cap Split
- Large Cap29.16%
- Mid Cap30.08%
- Small Cap37.53%
- Others3.23%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 43.73 | 41.94 |
| P/B | 6.57 | 6.29 |
| Price / Sales | 6.30 | 6.05 |
| Price / Cash Flow | 32.99 | 31.26 |
| Dividend Yield (%) | 0.52 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Divis Laboratories | Pharmaceuticals & Biotechnology | 9.39% | -0.15% |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 8.28% | -0.66% |
| TREPS - Tri-party Repo | Reverse Repo / TREPS | 4.67% | — |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 4.64% | +1.58% |
| Cipla | Pharmaceuticals & Biotechnology | 4.15% | +0.21% |
| Apollo Hospitals | Equity | 3.69% | +2.30% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.65% | -0.43% |
| Max Healthcare Institute | Equity | 3.61% | -0.45% |
| Aster DM Quality Care | Equity | 3.56% | -0.28% |
| Lupin | Pharmaceuticals & Biotechnology | 3.55% | -0.49% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 3.24% | -0.46% |
| Shilpa Medicare | Pharmaceuticals & Biotechnology | 3.23% | +0.13% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 3.19% | +1.29% |
| Acutaas Chemicals | Pharmaceuticals & Biotechnology | 3.18% | -0.06% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 3.17% | -0.31% |
View all 40 holdings
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.98% | -0.25% |
| Global Health | Equity | 2.72% | -0.13% |
| Rubicon Research | Pharmaceuticals & Biotechnology | 2.52% | -0.30% |
| Krishna Institute of Medical Sciences | Equity | 2.10% | -0.15% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.09% | -0.25% |
| Molbio Diagnostics | Equity | 2.01% | +0.24% |
| Vijaya Diagnostic Centre | Equity | 2.00% | -0.24% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 1.82% | -0.11% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 1.78% | +0.69% |
| Wockhardt | Pharmaceuticals & Biotechnology | 1.71% | +0.10% |
| Jupiter Life Line Hospital | Equity | 1.68% | -0.26% |
| Metropolis Healthcare | Equity | 1.67% | -0.23% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 1.58% | -0.02% |
| Biocon | Pharmaceuticals & Biotechnology | 1.47% | -0.26% |
| Symbiotec Pharmalab | Pharmaceuticals & Biotechnology | 1.36% | +0.15% |
| Thyrocare Technologies | Equity | 1.10% | -0.21% |
| Corona Remedies | Pharmaceuticals & Biotechnology | 1.04% | -0.03% |
| Entero Healthcare Solutions | Retailing | 1.01% | — |
| Jubilant Pharmova | Pharmaceuticals & Biotechnology | 0.93% | +0.08% |
| Eris Lifesciences | Pharmaceuticals & Biotechnology | 0.92% | -0.14% |
| Novartis | Pharmaceuticals & Biotechnology | 0.55% | +0.08% |
| Bajaj HealthCare | Pharmaceuticals & Biotechnology | 0.53% | -0.04% |
| Laxmi Dental | Equity | 0.35% | -0.03% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 0.32% | -0.02% |
| Net Current Assets | Net Current Assets | -1.44% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.69 | 16.32 | Low Volatility |
| 3Y | 14.24 | 16.10 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.15 | -0.32 | Above Average |
| 3Y | 1.42 | -0.45 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.64 | 0.19 | Above Average |
| 3Y | 2.94 | 1.14 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.03 | 0.96 | Poor Risk Adjusted Returns |
| 3Y | 0.98 | 0.96 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
|
SBI HEALTHCARE OPPORTUNITIES FUND
Regular Plan · IDCW
|
+18.71% | +23.84% | +18.25% | +12.20% |
More From HDFC Asset Management Company Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
HDFC Silver ETF
Growth Option
|
+25.77% | +36.06% | — | +34.08% |
|
HDFC Silver ETF Fund of Fund
Direct Plan · Growth Option
|
+25.37% | +35.62% | — | +32.02% |
|
HDFC Defence Fund
Direct Plan · Growth Option
|
+19.94% | +36.01% | — | +38.17% |
|
HDFC Developed World Overseas Equity Passive FOF
Direct plan · Growth
|
+18.91% | +25.41% | +15.25% | +16.26% |
|
HDFC Gold ETF
Growth Option
|
+16.82% | +30.99% | +23.25% | +12.15% |
|
HDFC Gold ETF Fund of Fund
Direct Plan · Growth Option
|
+16.53% | +30.86% | +23.07% | +10.47% |
|
HDFC INNOVATION FUND
Direct Plan · IDCW Option
|
+13.31% | — | — | +14.01% |
|
HDFC CRISIL-IBX Financial Services 3-6 Months Debt Index Fund
Direct Plan · Growth Option
|
+6.94% | — | — | +6.95% |
|
HDFC Arbitrage Fund
Direct Plan · Growth Option
|
+6.62% | +7.25% | +6.74% | +6.44% |
|
HDFC Credit Risk Fund
Direct Plan · IDCW Option
|
+6.53% | +8.11% | +7.12% | +7.95% |
About This Scheme
Investment Objective
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Equity and Equity related instruments of Pharma and healthcare companies/entities# : 80%- 100%; Equity and equity related instruments of companies/entities other than above: 0% - 20%; Units of InvITs: 0% - 10%; Money market instruments, Other liquid instruments and Units of Mutual Fund^^: 0% - 20%; Gold and Silver instruments: 0% - 20% #Indicative list of businesses forming part of the Pharma and healthcare companies/entities are as follows: • Pharmaceutical • Healthcare • Hospitals & Diagnostics • Health IT services • Research and/or Manufacturing Services related to healthcare • Distribution related to healthcare • Medical Equipment • Hygiene • And any other business or service directly or indirectly forming part of the pharma, healthcare and allied sectors forming part of the Benchmark Index. ^^Units of Domestic Mutual Funds shall only include Overnight Funds, Liquid Funds and Money Market Mutual Funds. Further other liquid instruments shall include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by SEBI from time to time. For detailed asset allocation, refer Scheme Information Document (SID) available on the website.
Exit Load
In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed /switched-out within 30 days from the date of allotment. No Exit Load is payable if units are redeemed / switched out after 30 days from the date of allotment.
Fund Managers
FM 1 - Mr. Nikhil Mathur, FM 2 - Mr. Gopal Agrawal, FM 3 - Mr. Bhagyesh Kagalkar
FM 1 - Fund Manager of the scheme, FM 2 - Fund Manager for Overseas Investments, FM 3 - Fund Manager for investments in Gold/Silver instruments
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.